Policy & Regulation
Elixirgen Therapeutics completes pre-Investigational New Drug meeting for COVID-19 vaccine candidate
5 June 2020 -

Elixirgen Therapeutics Inc, a Baltimore-based biotechnology company, has completed its pre-Investigational New Drug (pre-IND) meeting with the United States Food and Drug Administration (FDA) for EXG-5003, the company's COVID-19 vaccine candidate, it was reported on Thursday.

The product is a temperature-sensitive, intradermally-injected srRNA (self-replicating RNA) vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein.

The company says that EXG-5003 was designed with unique features that have potential dose sparing and safety benefits. It is continuing active development of the product toward a planned phase one clinical trial.



Related Headlines